Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.32−0.18 (-2.12%)
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
Ginkgo Bioworks price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ginkgo Bioworks's price to sales ratio was 4.9× on Nov 11, 2026, against 3.5× a year earlier. Over the last 5 years it ranged from 1.4× to 62.6×, with a median of 5.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.9× | +1.8 |
| 2025 | Dec 31, 2025 | 3.1× | +0.7 |
| 2024 | Dec 31, 2024 | 2.4× | −8.2 |
| 2023 | Dec 29, 2023 | 10.6× | +5.3 |
| 2022 | Dec 30, 2022 | 5.3× | −57.3 |
| 2021 | Dec 31, 2021 | 62.6× | – |
See a number that looks wrong?